By Fineline Cube 
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a revenue of RMB 1.206 billion (USD 166.3 million), a 1.61% year-on-year (YOY) increase. Operating profit reached RMB 661 million (USD 91.1 million), up 15.22% YOY, while net profit was RMB 502 million (USD 69.2 million), up 1.96% YOY.
Company Overview
MicroPort Endovascular is a leading Chinese manufacturer of aortic and peripheral vascular interventional medical devices. Its primary product is the aortic stent graft system, which is widely used in treating aortic-related conditions.
Product Portfolio
The company offers a comprehensive range of peripheral vascular interventional devices, including:
- Peripheral balloon dilation catheters
- Peripheral vascular stent systems
- Fiber hair embolization spring coils
- Vena cava filters
- Filter retrievers
Unique Product Advantage
Notably, MicroPort Endovascular holds the only intraoperative stent system approved in China for use in thoracic aortic dissection surgery, highlighting its innovation and market leadership in the field of vascular interventions.-Fineline Info & Tech